科瑞产品

- 客户定制产品 - 前列腺素系列 - PI3K Inhibitors - C-Kit Inhibitors - VEGFR Inhibitors - mTOR Inhibitors - c-Met Inhibitors - DNA/RNA Inhibitors - HER2 Inhibitors - Raf Inhibitors - JAK Inhibitors - Others - SRC Inhibitors - AKT Inhibitors - CDK Inhibitors

浙江省台州市椒江开发大道东段288号万达广场2号楼

0576-88813233

0576-88670057

sales@crene.cn

合作客户/Partner

当前位置：科瑞产品

福他替尼 Fostamatinib

规格	价格	库存	数量
在线咨询大包装询价加入购物车

如您需要更多数量的报价，请点击立即获取报价或者通过电子邮件sales@crene.cn把您需要的数量信息提交给我们我们会在第一时间回复您，谢谢！

产品信息

产品名称：福他替尼 Fostamatinib	纯度：98% min
CAS NO：901119-35-5	溶解度：116 mg/mL (199.84 mM)
分子式：C₂₃H₂₆FN₆O₉P	包装：可按客户要求包装
分子量：580.46	贮存：-20 ℃

质量控制

备注说明

Fostamatinib is an experimental drug candidate for the treatment of a variety of diseases, originally developed by Rigel Pharmaceuticals. The drug is administered orally as a disodium salt, and is a prodrug of the active compound tamatinib (R-406), which is an inhibitor of the enzyme spleen tyrosine kinase (Syk), hence it is an syk inhibitor.

参考文献

[1]. Chen L, Monti S, Juszczynski P, et al. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma[J]. Blood, 2008, 111(4): 2230-2237.

[2]. Suljagic M, Longo P G, Bennardo S, et al. The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Eμ-TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling[J]. Blood, 2010, 116(23): 4894-4905.